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Suboptimal laboratory diagnostics for Clostridium 
difficile infection (CDI) impedes its surveillance and 
control across Europe. We evaluated changes in local 
laboratory CDI diagnostics and changes in national 
diagnostic and typing capacity for CDI during the 
European C. difficile Infection Surveillance Network 
(ECDIS-Net) project, through cross-sectional surveys 
in 33 European countries in 2011 and 2014. In 2011, 
126 (61%) of a convenience sample of 206 laborato-
ries in 31 countries completed a survey on local diag-
nostics. In 2014, 84 (67%) of these 126 laboratories 
in 26 countries completed a follow-up survey. Among 
laboratories that participated in both surveys, use 
of CDI diagnostics deemed ‘optimal’ or ‘acceptable’ 
increased from 19% to 46% and from 10% to 15%, 
respectively (p  < 0.001). The survey of national capac-
ity was completed by national coordinators of 31 and 
32 countries in 2011 and 2014, respectively. Capacity 
for any C. difficile typing method increased from 22/31 
countries in 2011 to 26/32 countries in 2014; for PCR 
ribotyping from 20/31 countries to 23/32 countries, 
and specifically for capillary PCR ribotyping from 7/31 
countries to 16/32 countries. While our study indicates 
improved diagnostic capability and national capacity 
for capillary PCR ribotyping across European laborato-
ries between 2011 and 2014, increased use of ‘optimal’ 
diagnostics should be promoted.
Introduction
Since 2003, Europe has been affected by outbreaks 
of Clostridium difficile infection (CDI) associated with 
the emergence of PCR ribotype 027/NAP1 [1]. A decade 
later, C. difficile was the microorganism responsible for 
48% of healthcare-associated gastrointestinal infec-
tions in acute care hospitals across Europe [2]. Despite 
being frequent, CDI remains underestimated in most 
European countries [3]. Underdiagnosis mainly results 
from a lack of awareness among medical doctors of 
when to suspect that patients may have CDI and use 
of suboptimal diagnostic algorithms at local microbio-
logical laboratories [3-5]. Reference tests, i.e. toxigenic 
culture and cell culture cytotoxicity assay (CCA), are 
not suitable for routine application due to their com-
plexity and long turnaround time [6,7]. Rapid enzyme 
immunoassays (EIAs) to detect C. difficile toxins in fae-
ces lack sensitivity [6,8]. Highly sensitive tests such as 
EIA detecting glutamate dehydrogenase (GDH) – a C. 
difficile-specific enzyme [9] – or nucleic acid amplifica-
tion tests (NAATs) have insufficient specificity [6,10]. To 
overcome underdiagnosis and suboptimal performance 
of stand-alone tests, the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID) has 
recommended since 2009 testing loose stools using 
two-step algorithms that have a highly sensitive test 
as the first screening step and a highly specific test as 
the second confirmatory test [6,11]. The ‘Bristol stool 
scores’ [12] are commonly used to categorise stool 
consistencies and can be used to select samples for 
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Figure 1
Criteria for selection of faecal samples tested for Clostridium difficile among responding local laboratories that participated 
in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) project in 2011 (n = 120)a
0 10 20 30 40 50
All faecal samples
Loose stools
Healthcare-associated diarrhoea
Only on request of a medical doctor
Antibiotic-associated diarrhoea
Percentage of laboratories 
a Laboratories in 31 countries responded to the 2011 survey: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lichtenstein, Lithuania, Luxembourg, the Netherlands, Norway, 
Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom (not including Wales). Serbia did not 
participate in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) project in 2011. No laboratories in Slovakia and 
Wales were invited to participate by ECDIS-Net national coordinators in 2011.
Figure 2
Reported changes affecting national/subnational laboratory diagnostic capacity for Clostridium difficile infection between 
2011 and 2014 in participating European countries (n = 32)a
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Change in reimbursement of diagnostic tests
Change in legislation
Otherb
No change
New/revised national guidelines
Availability of tests on the market
Number of countries
a Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, 
Latvia, Lichtenstein, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, 
Sweden, Switzerland, Turkey and the United Kingdom (data were analysed separately for England, Northern Ireland, Scotland and Wales, 
but counted as one country). No data were available for Iceland.
b Seven countries reported other changes in national laboratory diagnostics: Slovenia was developing new national guidelines for CDI at 
the time of the second survey; Romania started a national surveillance study in 2014; Spain published an opinion document on CDI [32]; 
Slovakia was in the process of implementing new diagnostic methods due to an increased interest in CDI; in Cyprus, the central diagnostic 
laboratory for C. difficile implemented a two-step diagnostic algorithm; in Finland, CDI diagnostics were subcontracted to laboratory 
consortia that applied nucleic acid amplification tests more often; and Hungary relocated its national reference laboratory to expand its 
laboratory capacity but still had limited resources.
3www.eurosurveillance.org
Figure 3
Clostridium difficile typing methods available in countries that participated in the European Clostridium difficile Infection 
Surveillance Network (ECDIS-Net) project in 2011 (n = 31)a and 2014 (n = 32)a
Standard PCR ribotyping
Capillary PCR ribotyping
No PCR ribotyping
MLVA
MLST
Other typing method(s)
PFGE
A. 2011
B. 2014
MLVA
MLST
WGS
Other typing method(s)
PFGE
Standard PCR ribotyping
Capillary PCR ribotyping
No PCR ribotyping
PFGE: pulsed-field gel electrophoresis; MLST: multilocus sequence typing; MLVA: multilocus variable-number tandem repeat analysis; WGS: whole genome sequencing.
Other typing methods used in 2011 were: tcdC typing (Austria, Belgium, Finland, France, Italy, Latvia, Luxembourg (not shown), Spain, United Kingdom - Northern Ireland only), 
repetitive-element PCR (Belgium, Spain), toxinotyping (Italy, Spain), tandem repeat sequence typing (Denmark) and pathogenicity locus (PaLoc) multiplex PCR (Finland).
Other typing methods used in 2014 were: tcdA/B (Belgium, Romania, Slovakia), CDT (Belgium, Slovakia), tcdC (Belgium), Δ117TcdC (Slovakia), and GyrAΔ detection (Belgium) 
detection, tandem repeat sequence typing (Denmark), and high molecular weight typing by MALDI-TOF (Sweden).
a In 2011, 31 countries responded: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, 
Latvia, Lichtenstein, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United 
Kingdom (not including Wales). No data were available for Iceland. In 2011, Serbia did not participate in the European Clostridium difficile Infection Surveillance Network 
(ECDIS-Net) project. In 2014, Serbia participated in the ECDIS-Net project and responded to the 2014 questionnaire, as did Wales, and so the number of responding countries in 
2014 was 32.
Source of map: FreeVectorMaps.com (http://freevectormaps.com).
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CDI testing. ESCMID recommended performing CDI 
testing not only upon request of a medical doctor, but 
also based on other indications such as the ‘three-day 
rule’, i.e. diarrhoea after three days of hospitalisation 
or when diarrhoea develops after antibiotic use [6,13].
The type of diagnostic algorithm applied influences not 
only clinical care [14], but also CDI surveillance’s sen-
sitivity and specificity [3,14,15]. However, a consensus 
on when and how to test for CDI has not been estab-
lished among reference and local laboratories.
Additionally, typing of C. difficile to understand its 
local or wider transmission remains non-standardised 
in Europe [16,17]. Numerous typing methods have 
become available for routine use in the last 30 years. 
For C. difficile, these include methods that use restric-
tion enzymes (e.g. restriction endonuclease analysis, 
pulsed-field gel electrophoresis (PFGE)), PCR amplifica-
tion of housekeeping genes (e.g. multilocus sequence 
typing (MLST)), of repetitive elements (repetitive-ele-
ment PCR, multilocus variable-number tandem repeat 
analysis (MLVA)), of the pathogenicity locus (e.g. toxi-
notyping) or of 16S-23S rRNA intergenic spacer regions 
(e.g. PCR ribotyping) [16,18]. Whole genome sequenc-
ing, with its ultimate discriminatory power, can already 
be used for in-depth analysis of evolutionary patterns 
[19]. Nevertheless, PCR ribotyping still remains the 
standard typing method in Europe as it involves rela-
tively simple technology and its low costs permits 
widespread application [16,18].
In 2010, the European Centre for Disease Prevention 
and Control (ECDC) launched the European C. difficile 
Infection Surveillance Network (ECDIS-Net) project, an 
initiative to enhance and harmonise laboratory diag-
nostic and typing capacity for CDI, and to support 
surveillance of CDI in Europe. The project consortium 
consisted of a team of experts involved in the first 
European multicountry surveillance study performed 
in 2008 [20]. Between 2010 and 2014, the ECDIS-Net 
project developed standard operating procedures for 
C. difficile culturing and PCR ribotyping, implemented 
a reference nomenclature database and compiled a 
set of reference strains to standardise PCR ribotyping. 
National reference laboratories were invited to partici-
pate in a workshop for culturing and typing of C. diffi-
cile and participated in an external quality assessment 
exercise.
The study presented here measured changes in capac-
ity for diagnostic testing for CDI and typing of C. dif-
ficile isolates in Europe between 2011 and 2014, using 
surveys of European local laboratories and national 
coordinators participating in the ECDIS-Net project. 
Additionally, we aimed to obtain insight into barriers 
to optimal CDI laboratory diagnostics, to inform further 
activities of ECDC and of the ESCMID Study Group for 
C. difficile (ESGCD) in this field.
Methods
Study design
The Dutch National Reference Laboratory for C. diffi-
cile (Leiden University Medical Centre, Leiden, and the 
National Institute for Public Health and the Environment 
(RIVM), Bilthoven, the Netherlands) coordinated data 
collection in 2011 and in 2014 by cross-sectional sur-
veys among two target groups: (i) local microbiology 
laboratories, in order to evaluate changes in routine 
laboratory diagnostics; and (ii) national coordinators, 
i.e. representatives of national or regional reference 
laboratories nominated by competent bodies for sur-
veillance on the request of ECDC, to evaluate national 
changes in diagnostic and typing capacity for C. diffi-
cile. In 2011 and 2014, 32 and 33 countries participat-
ing in the ECDIS-Net project were invited to take part in 
Table 1
Criteria for categorisation of Clostridium difficile infection diagnostic algorithms, survey of European countries 
participating in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) project, 2011 (n = 31)a and 
2014 (n = 26)a
Categorisation of CDI diagnostics 
Screening test
CDI diagnostic algorithm
Confirmatory test
Optimalb
1c NAAT EIA toxin detection
2–3c GDH EIA and toxin detection NAAT or toxigenic culture
Acceptableb
4–5c GDH EIA detection NAAT or toxigenic culture
6c NAAT None
Incompleteb 7–10c All other algorithms
CDI: Clostridium difficile infection; EIA: enzyme immunoassay; GDH: glutamate dehydrogenase; NAAT: nucleic acid amplification test.
a Laboratories in 31 countries responded to the 2011 survey: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lichtenstein, Lithuania, Luxembourg, the Netherlands, Norway, 
Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom (not including Wales). Serbia did not 
participate in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) project in 2011. No laboratories in Slovakia and 
Wales were invited to participate by ECDIS-Net national coordinators in 2011. Laboratories in 26 countries responded in 2014 (no data from 
laboratories in Croatia, Iceland, Latvia, Slovenia and Switzerland). 
b Categorisation of CDI diagnostic algorithms in the second survey, in 2014 [21].
c Corresponding CDI diagnostic algorithms in the second survey, in 2014 [21].
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the survey, respectively (in 2011, Serbia did not partici-
pate in ECDIS-Net). All surveys are available online [21].
Selection
There was no European register of microbiology labo-
ratories to use for random sampling. Therefore, ECDIS-
Net national coordinators were requested to invite a 
representative sample of the local clinical microbiology 
laboratories (about 10%) in each country to participate 
in the survey. In Austria and Norway, the laboratories 
were selected by random sampling; all other countries 
used non-random convenience sampling [22]. Selected 
laboratories were emailed an initial survey in October 
2011: some laboratories replied in 2012. All respond-
ents to the initial survey received a follow-up survey in 
June 2014.
Data collection
Data were collected through a centralised web-based 
system (Questback, New York, United States). In 2011, 
the initial survey contained questions on several 
aspects of local routine diagnostics, including indica-
tions for undertaking CDI diagnostics and methodolo-
gies. Laboratories were requested to report the type of 
screening test primarily used for CDI diagnostics and 
confirmatory test (if applicable). For both, they could 
report more than one test. In 2014, the follow-up sur-
vey listed 10 diagnostic algorithms each designated as 
either ‘optimal’, ‘acceptable’ or ‘incomplete’ (Table 1). 
Laboratories were requested to estimate the percent-
age of samples that had been tested according to each 
algorithm listed, or to describe their usual diagnostic 
algorithm and estimate the corresponding percentage. 
The categorisation of CDI diagnostic algorithms was 
made by some of the ECDIS-Net experts who were also 
involved in revising the ESCMID diagnostics guidelines 
for CDI [6]. Algorithms designated as optimal had high 
sensitivity and specificity (not specifically defined), 
detection of free toxins in faeces and a rapid turna-
round time [23]. Acceptable algorithms met the same 
criteria but without detecting free toxins in faeces. Any 
other algorithm was designated as incomplete. The 
2014 follow-up survey additionally contained ques-
tions on barriers to apply optimal or acceptable diag-
nostic algorithms and changes in the indications for 
sending samples for CDI diagnosis by medical doctors.
Data analysis
To allow comparison, data on diagnostics from the 
2011 initial survey were distributed into the three cat-
egories of diagnostic algorithms defined in 2014. For 
each local laboratory, CDI diagnostics, i.e. CDI testing 
practices, were considered optimal if more than 80% of 
the samples followed an optimal diagnostic algorithm, 
and acceptable if more than 80% of the samples fol-
lowed either an optimal or acceptable algorithm. CDI 
diagnostics of all other algorithms were considered 
incomplete. When a laboratory reported a three-step 
algorithm by applying a third diagnostic test when the 
screening and confirmatory tests were contradictory, 
this algorithm was allocated to the best-matching two-
step algorithm. Changes in local laboratory diagnostic 
capacity were evaluated by the McNemar’s test [24], 
and changes in the use of optimal, acceptable and 
incomplete algorithms in 2011 and 2014 were evaluated 
by a Bowker test for symmetry [24]. A sensitivity analy-
sis was performed using two assumptions on missing 
data in 2014, i.e. CDI diagnostics one category inferior 
(Table 1) than in 2011 and CDI diagnostics one category 
superior than in 2011. Data were analysed using IBM 
SPSS statistics 20 (SPSS Inc., Chicago, United States). 
Survey of ECDIS-Net national coordinators
Data collection and analysis
All ECDIS-Net national coordinators received an ini-
tial survey in May 2011 and a follow-up survey in June 
2014. Both surveys contained questions on national 
typing capacity (defined as any laboratory in the coun-
try performing typing) and on molecular typing meth-
ods, asking which were available in their country from 
a list of common methods [18]. 
Results
Local laboratory capacity
Participants
Questionnaires on local diagnostic and typing capacity 
for CDI were completed by 126 (61%) of 206 laborato-
ries in 2011–12 and by 84 (67%) of these same 126 lab-
oratories in 2014 (Table 2). A total 124 (98%) of the 126 
responding laboratories in 2011–12 provided microbio-
logical services to hospitals, of which 103 (83% ) served 
at least one university, secondary or tertiary care hos-
pital. In addition, 66 (53%) provided microbiological 
services to long-term care facilities, of which 45 pro-
vided services to nursing homes. Furthermore, 65/124 
(52%; data were missing for two laboratories) provided 
medical services to other healthcare services (e.g. gen-
eral practitioners). In 2011 and 2014, 120/126 (95%) 
and 83/84 laboratories (99%, among responders to 
both questionnaires; p = 0.50), respectively, reported 
that they performed CDI laboratory diagnostics.
Indications for Clostridium difficile infection diagnostics
The indications for CDI diagnostics reported in 2011 are 
listed in Figure 1. In 2014, a change of indications for 
sending samples for CDI diagnosis by medical doctors 
was observed; 16 (19%) of 83 laboratories reported 
that one or two changes had occurred since 2011. 
Several laboratories introduced the use of Bristol stool 
scores to assess stool consistency for sample selec-
tion (n = 5). Also, patient populations that were previ-
ously not monitored for CDI (e.g. outpatients, high-risk 
populations) were later explicitly included in protocols 
(n = 3) and awareness and recognition of CDI among 
clinicians had improved (n = 5). Other improvements of 
sample selection were also reported (n = 5), i.e. appli-
cation of guidelines for sample selection (n = 3) and/
or the three-day rule, i.e. diarrhoea after three days 
6 www.eurosurveillance.org
of hospitalisation (n = 1), and unspecified attempts to 
improve sample selection (n = 1).
C. difficile infection diagnostics
In 2011, 17 (14%) of 120 laboratories had optimal CDI 
diagnostics, 12 (10%) acceptable diagnostics and 91 
(76%) incomplete diagnostics (Table 3). Incomplete 
algorithms included use of EIA toxin detection for 
screening with or without a confirmatory test, or a com-
bination of EIA GDH and toxin detection without other 
tests for confirmation. Among laboratories responding 
to both the 2011 and 2014 surveys and that performed 
CDI diagnostics at both time-points (n = 81), the per-
centage of laboratories with optimal CDI diagnostics 
Table 2
Response of participating European countries to local laboratory (n = 31 and n = 26, respectively) and national/subnational 
surveys (n = 31 and n = 32, respectively) on Clostridium difficile infection diagnostic and typing capacity, 2011 and 2014
Country
Number of laboratories that responded to local questionnaire /
number invited Replied to national questionnaire
a
2011 2014 2011 2014
Austria 4/8 2/4 Yes Yes
Belgium 4/9 4/4 Yes Yes
Bulgaria 7/7 2/7 Yes Yes
Croatia 2/4 0/2 Yes Yes
Cyprus 3/3 3/3 Yes Yes
Czech Republic 9/11 7/9 Yes Yes
Denmark 3/3 1/3 Yes Yes
Estonia 2/2 1/2 Yes Yes
Finland 3/3 2/3 Yes Yes
France 5/37 2/5 Yes Yes
Germany 5/7 5/5 Yes Yes
Greece 3/3 2/3 Yes Yes
Hungary 8/8 8/8 Yes Yes
Iceland 1/1 0/1 No No
Ireland 3/5 2/3 Yes Yes
Italy 13/14 8/13 Yes Yes
Latvia 2/3 0/2 Yes Yes
Lichtenstein 1/1 1/1 Yes Yes
Lithuania 3/3 2/3 Yes Yes
Luxembourg 2/6 1/2 Yes Yes
Netherlands 4/6 3/4 Yes Yes
Norway 9/13 4/9 Yes Yes
Poland 6/6 4/6 Yes Yes
Portugal 4/5 4/4 Yes Yes
Romania 4/6 3/4 Yes Yes
Serbiab NA NA NA Yes
Slovakiac NA NA Yes Yes
Slovenia 1/3 0/1 Yes Yes
Spain 3/5 2/3 Yes Yes
Sweden 2/3 2/2 Yes Yes
Switzerland 1/1 0/1 Yes Yes
Turkey 2/7 2/2 Yes Yes
UK-England 2/6 2/2 Yes Yes
UK-Northern Ireland 1/3 1/1 Yes Yes
UK-Scotland 4/4 4/4 Yes Yes
UK-Walesc NA NA No Yes
Total 126/206 84/126 31 32 
NA: not applicable; UK: United Kingdom.
a For the UK, data were analysed separately for England, Northern Ireland, Scotland and Wales, but the UK was counted as one country.
b Serbia did not participate in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) project in 2011.
c No laboratories in Slovakia and Wales were invited to participate by ECDIS-Net national coordinators. 
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increased from 19% to 46% and that with acceptable 
CDI diagnostics from 10% to 15% while the percent-
age of laboratories with incomplete CDI diagnostics 
decreased from 72% to 40% (p  < 0.001; Table 3). Two 
laboratories without any diagnostics in 2011 had opti-
mal and incomplete CDI diagnostics, respectively, in 
2014.
Sensitivity analysis
Laboratories with optimal CDI diagnostics in 2011 were 
more likely to respond to the 2014 survey (15/17) com-
pared with those with acceptable (8/12) or incomplete 
diagnostics (58/91). Under the negative assumption 
that all non-responding laboratories in 2014 applied 
CDI diagnostics one category inferior in 2014 compared 
with that of 2011, the percentage of laboratories with 
optimal diagnostics would have increased from 14% 
to 31%, that with acceptable diagnostics would have 
increased from 10% to 12%, and that with incomplete 
diagnostics would have decreased from 76% to 58% 
between 2011 and 2014 (p  < 0.001). Conversely, if all 
non-responding laboratories had CDI diagnostics one 
category superior in 2014 compared with 2011, the per-
centage of laboratories with optimal diagnostics would 
have increased from 14% to 36%, that with acceptable 
diagnostics would have increased from 10 to 38%, and 
that with incomplete diagnostics would have decreased 
from 76 to 27% between 2011 and 2014 (p  < 0.001).
Barriers to optimal/acceptable diagnostics for C. difficile 
infection
Barriers to applying optimal or acceptable algorithms 
were examined in 2014. Of the 33 laboratories with 
incomplete CDI diagnostics, 17 indicated that materials 
or tests were too costly, six indicated receiving insuf-
ficient reimbursement for tests from insurers and five 
had insufficient availability of trained staff. Of the 50 
laboratories that had optimal or acceptable CDI diag-
nostics, 10 also indicated that materials or tests were 
too costly, seven indicated receiving insufficient reim-
bursement from insurers and five had insufficient avail-
ability of trained staff. Ten laboratories that responded 
in 2014 indicated that they disagreed with the project’s 
designations of the CDI diagnostic algorithms as opti-
mal, acceptable or incomplete.
National/subnational capacity
Participating countries
The national coordinators of 31 and 32 countries 
responded to the national survey in 2011 and 2014, 
respectively (Table 2). Data were collected separately 
for the four countries within the United Kingdom (UK), 
i.e. England, Northern Ireland, Scotland and Wales, but 
the UK was counted as one country.
Changes in national diagnostic capacity
In 2014, eight of the 32 responding countries (France, 
Germany, Greece, Latvia, Luxembourg, Sweden, 
Switzerland, Turkey) reported no change in national/
subnational laboratory diagnostics for CDI. Conversely, 
24 countries reported one or more changes in national/
subnational laboratory diagnostics for CDI since 2011 
(Figure 2). Specifically, 16 countries had experienced 
a change in availability of commercial diagnostic tests 
(Bulgaria, Czech Republic, Estonia, Hungary, Ireland, 
Italy, Lichtenstein, Lithuania, the Netherlands, Norway, 
Poland, Portugal, Romania, Serbia, Slovenia, UK), 10 
countries had new or revised guidelines for CDI diag-
nostics (Austria, Czech Republic, Denmark, Estonia, 
Hungary, Ireland [25], Italy, Lithuania, Romania, UK) 
and three countries had changes in relevant legislation 
(Hungary, Poland, Romania). Three countries (Belgium, 
Croatia, Czech Republic) had implemented changes in 
reimbursement policies for diagnostic tests. Greece 
had limited access to and reimbursement of materials 
in both 2011 and 2014. In 2012, the UK implemented 
‘harmonised’ diagnostics using GDH screening (or 
NAAT) and EIA toxin detection (or CCA) in all its labo-
ratories [26].
C. difficile national typing methods
The capacity for various C. difficile typing methods in 
participating countries in 2011 and 2014 is depicted 
in Figure 3. The number of countries able to perform 
any method of typing increased from 22/31 countries 
in 2011 to 26/32 countries in 2014. Only six countries 
(Croatia, Cyprus, Estonia, Lichtenstein, Lithuania, 
Serbia) reported that they did not have any national 
typing capacity in 2014 (none of these countries had 
typing capacity in 2011); however, Lichtenstein sent 
samples to another country (Austria) for typing.
Several typing methods were implemented by the 
countries (Figure 3). PCR ribotyping (either capillary-
based or conventional agarose gel-based), the current 
European standard for C. difficile typing, was avail-
able in 20/31 countries in 2011 and in 23/32 countries 
in 2014. Two of the countries that acquired ribotyp-
ing capacity (Ireland and Romania) use it for national 
surveillance. Capillary PCR ribotyping was applied by 
7/31 countries in 2011 and by 16/32 countries in 2014. 
In 2014, nine of the 32 participating countries applied 
MLVA, six PFGE and seven MLST. In 2014, whole 
genome sequencing was available in Germany, the 
Netherlands, Norway, Slovenia and England.
Some countries reported specific changes in national 
molecular typing capacity between 2011 and 2014. 
Greece, which previously did not have typing capac-
ity, introduced MLST in January 2014. At the time of 
the 2014 survey, Estonia was capable of ribotyping for 
research projects, although there were no such pro-
jects. Turkey performed PCR ribotyping but lacked soft-
ware to analyse the data. Denmark stopped using PCR 
ribotyping and only applied tandem repeat sequence 
typing. Hungary reported limited typing capacity for 
financial reasons although PCR ribotyping remained 
available at the national reference laboratory. Finland 
restricted the indications for ribotyping to severe CDI 
or outbreaks, which unintentionally caused many 
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laboratories to stop all culturing and/or sending iso-
lates for typing.
Discussion
This study assessed changes in diagnostic testing 
and typing capacity for CDI in Europe between 2011 
and 2014, using surveys of European local labora-
tories and of national coordinators participating in 
the ECDIS-Net project. Virtually all participating local 
laboratories had implemented CDI diagnostics in 2011 
and 2014, compared with 88% (186/212) of the local 
laboratories investigated in eight European countries 
in 2003 [27]. The percentage of laboratories with opti-
mal CDI diagnostics increased from 19% to 46%, and 
that with acceptable diagnostics increased from 10% 
to 15%. Importantly, the ESCMID-recommended two-
step diagnostic algorithm [6] became more common. 
Nevertheless, we still observed a considerable varia-
tion in CDI diagnostics within and between European 
countries, in line with another European study with 482 
participating hospitals in 2011–13 [3]. This variation in 
diagnostics can substantially affect CDI incidence rates 
obtained by surveillance [15,28]. Our survey showed 
that suboptimal CDI diagnostics may result from, for 
example, financial restrictions or limited availability 
of trained staff. As a consequence of the disagreement 
by a sizable minority of laboratories with the designa-
tion of diagnostic algorithms, the ESGCD undertook 
to revise its diagnostic guidelines [6] and propose an 
algorithm that can also be implemented in laborato-
ries with limited numbers of trained staff and limited 
financial resources. These revised guidelines will be 
published in 2016 on behalf of ESCMID. 
Among countries having national guidelines avail-
able, the UK was the only one that had succeeded in 
harmonising CDI diagnostics, by recommending a sin-
gle two-test diagnostic algorithm (‘comprising a GDH 
EIA (or NAAT/PCR) followed by a sensitive toxin EIA’) 
[3,26]. The recommendations in the UK Department of 
Health guidance were supported by local study data 
and inclusion of frequently asked questions to allay 
objections of the laboratories to implementing the 
proposed diagnostic algorithms [26]. Furthermore, 
the diagnostics guidance was one of many C. difficile-
related activities in the UK, for example, implementa-
tion of mandatory CDI reduction targets with financial 
penalties for national health services [29]. There prob-
ably are two possible ways to optimise testing: either 
to promote one national diagnostic algorithm or to 
promote the use of optimal testing strategies by local 
laboratories. However, the proposed algorithm in the 
UK was not fully compliant with the designation of 
diagnostic algorithms as optimal in this survey, high-
lighting the need for further discussion among experts 
to reach a consensus. Another example is Spain, where 
several national studies and meetings were organ-
ised [30,31] that resulted in an opinion document to 
enhance optimal diagnostics for CDI [32]. We hope that 
the national reference laboratories that participated in 
the ECDIS-Net project will follow these examples and 
promote optimal diagnostics for CDI and its implemen-
tation in local laboratories.
Typing capacity
Between 2011 and 2014, PCR ribotyping capacity and 
capillary PCR ribotyping increased among the par-
ticipating countries. Capillary PCR ribotyping was 
validated in 2012–14 by four reference laboratories 
in England, the Netherlands, the United States and 
Canada, identifying a 98% consensus (195/200 cases 
tested) between the laboratories, which indicated the 
Table 3
Laboratories participating in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) project 
according to their diagnostics category, 2011 (n = 120)a and 2014 (n = 81)a
Categorisation of CDI diagnosticsb
All laboratories that provided 
data
Only laboratories that provided data in both 2011 and 
2014 surveys
2011 2011 2014c
n (%) n (%)d n (%)d
Optimal 17 (14) 15 (19) 37 (46)
Acceptable 12 (10) 8 (10) 12 (15)
Incomplete 91 (76) 58 (72) 32 (40)
Total 120 (100) 81 (100) 81 (100) 
CDI: Clostridium difficile infection.
a Laboratories in 31 countries responded to the 2011 survey: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lichtenstein, Lithuania, Luxembourg, the Netherlands, Norway, 
Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom (not including Wales). Serbia did not 
participate in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) project in 2011. No laboratories in Slovakia and 
Wales were invited to participate by ECDIS-Net national coordinators in 2011. Laboratories in 26 countries responded in 2014 (no data from 
laboratories in Croatia, Iceland, Latvia, Slovenia and Switzerland).
b CDI diagnostics were considered ‘optimal’ if > 80% of the samples followed an ‘optimal’ testing algorithm, and ‘acceptable’ if > 80% of 
the samples followed either an ‘optimal’ or ‘acceptable’ testing algorithm. CDI diagnostics of all other laboratories were considered 
‘incomplete’. The diagnostic algorithms are described in Table 1.
c Two laboratories that did not perform CDI laboratory diagnostics in 2011 were not included. These laboratories indicated in the 2014 
questionnaire that they used optimal and incomplete CDI diagnostics, respectively. 
d The percentages in this column do not add up to 100 due to rounding.
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method’s suitability for standardised CDI surveillance 
[17].
We assume that ECDIS-Net activities during 2012–14, 
including a training programme for C. difficile PCR 
ribotyping, contributed to the increased PCR ribotyping 
capacity. For example, Romania joined the training pro-
gramme in 2012 and received a set of reference strains 
from the ECDIS-Net project and is now able to apply 
PCR ribotyping in their national surveillance. Poland 
reported having started their first national surveil-
lance programme, stimulated by ECDIS-Net activities 
in 2012 [33]. A few countries (Hungary, Italy, Slovenia) 
had national surveillance under development at time 
of the 2014 survey. Despite these positive trends, our 
study also indicates that some European reference and 
local laboratories are affected by limited resources and 
budget reductions, which hamper implementation and 
technical improvements of molecular typing methods.
Limitations
This study has several limitations including the small, 
non-random selection of local laboratories for both 
surveys and the moderate response rate, limiting the 
degree to which conclusions can be extrapolated to all 
European microbiological laboratories. The represent-
ativeness of the invited and participating laboratories 
could not be assessed due to the absence of a suitably 
complete European register. Laboratories with better 
CDI diagnostics may have been more likely to partici-
pate in the original and follow-up surveys, leading to 
an overestimation of the number of laboratories with 
optimal CDI diagnostics in Europe. Additionally, the 
categorisation of CDI diagnostic algorithms into three 
levels, although made through a series of consultations 
with a team of international experts from the ECDIS-Net 
project, was based on expert opinion and some sub-
jectivity cannot be excluded. Also, although the 2014 
questionnaire for local laboratories requested quan-
titative data on the percentage of tests that followed 
each algorithm on a provided list, as the list had the 
subheadings ‘optimal’, ‘acceptable’ and ‘incomplete’, 
it is possible that those responding overestimated the 
proportion of desirable answers. We estimate that this 
reporting bias was minimal as for almost all laborato-
ries, just one algorithm was used.
Conclusions
We conclude that the ECDIS-Net project laid the foun-
dations for Europe-wide surveillance of CDI, although 
increased use of optimal diagnostic algorithms should 
be promoted, taking into consideration the limited 
resources and budget cuts in several European coun-
tries. The ESGCD revised the ESCMID diagnostics 
guidelines for CDI, which, once published, should con-
tribute to standardisation of CDI diagnostics at local 
and national level in Europe. Typing capacity for CDI 
in Europe was acceptable overall; however, an interna-
tionally standardised capillary PCR ribotyping protocol 
is now available [17] and requires further implemen-
tation in European countries. We would recommend 
that these important steps are considered as part of 
the integration of C. difficile molecular typing data in 
The European Surveillance System (TESSy), within the 
ECDC-coordinated Europe-wide CDI surveillance (since 
1 January 2016) [34].
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